Chronic Obstructive Pulmonary Disease Forecast and Market Analysis to 2026

Figure 1: Trends in prevalent cases of COPD, 2018–27
Figure 2: Overview of pipeline drugs for COPD in the US
Figure 3: Pipeline drugs for COPD, by company
Figure 4: Pipeline drugs for COPD, by drug type
Figure 5: Pipeline drugs for COPD, by classification
Figure 6: Probability of success in the COPD pipeline
Figure 7: Clinical trials in COPD
Figure 8: Top 10 drugs for clinical trials in COPD
Figure 9: Top 10 companies for clinical trials in COPD
Figure 10: Trial locations in COPD
Figure 11: COPD trials status
Figure 12: COPD trials sponsors, by phase
Figure 13: The publisher’s drug assessment summary for COPD
Figure 14: Market dynamics in COPD
Figure 15: Future trends in COPD
Figure 16: Breztri Aerosphere for COPD (June 24, 2020): Phase III - ETHOS
Figure 17: RPL554 (Inhaled) for COPD (March 31, 2020): Phase II - Metered-Dose Inhaler (MDI) Formulation
Figure 18: Key upcoming events in COPD

Table 1: Modified British Medical Research Council (mMRC) Questionnaire
Table 2: COPD Assessment Test (CAT)
Table 3: COPD assessment, by spirometric grade
Table 4: The “ABCD” assessment tool
Table 5: Inhaled bronchodilators for COPD, by class
Table 6: Combination therapies for COPD, by class
Table 7: Prevalent cases of COPD, 2018–27
Table 8: Marketed drugs for COPD
Table 9: Pipeline drugs for COPD in the US
Table 10: Historical global sales, by drug ($m), 2015–19
Table 11: Forecasted global sales, by drug ($m), 2021–25
Table 12: Trelegy Ellipta for COPD (August 31, 2020)
Table 13: Trelegy Ellipta for COPD (August 28, 2020)
Table 14: Breztri Aerosphere for COPD (June 24, 2020)
Table 15: RPL554 (Inhaled) for COPD (March 31, 2020)
Table 16: Breztri Aerosphere for COPD (October 1, 2019)